Evidence map›Paper›PMID 22132889›Full record

ArticleClinical and experimental immunology2012

Essential role of the adaptor protein Nck1 in Jurkat T cell activation and function.

I Yiemwattana, J Ngoenkam, P Paensuwan, R Kriangkrai, B Chuenjitkuntaworn, S Pongcharoen

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05218434 phase1completednot on this mapstarted 2021, after this paper: background citation

A Randomised, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AX-158 Following Administration of Single and, Multiple Ascending Oral Doses and Food Effect Sub-study in Healthy Male Volunteers

TypeinterventionalSponsorArtax Biopharma IncRan2021 to 2022Enrolled64ConditionsAutoimmune DiseasesArmsAX-158
NCT05725057 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

TypeinterventionalSponsorArtax Biopharma IncRan2023 to 2024Enrolled31ConditionsPsoriasis, Plaque PsoriasisArmsAX-158, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

I YiemwattanaDepartment of Preventive Dentistry, Faculty of Dentistry, Naresuan University, Phitsanulok, Thailand.
J Ngoenkam
P Paensuwan
R Kriangkrai
B Chuenjitkuntaworn
S Pongcharoen
Naresuan University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The non-catalytic region of tyrosine kinase (Nck) is proposed to play an essential role in T cell activation. However, evidence based on functional and biochemical studies has brought into question the critical function of Nck. Therefore, the aim of the present work was to investigate the role of Nck in T cell activation. To study this, the human Jurkat T cell line was used as a model for human T lymphocytes. The short interfering (si) RNA targeting Nck1 gene was used with electroporation to knock-down Nck1 protein expression in Jurkat T cells. Primary human CD4 T cells were also transfected with the siRNA of Nck1. The results showed that decreased Nck1 protein expression did not affect the apoptosis of the transfected Jurkat T cells compared with control siRNA-transfected cells and non-transfected cells. Upon CD3ε/CD28 stimulation, knock-down of Nck1 in Jurkat T cells caused a decrease in CD69 expression and in interleukin (IL)-2 secretion. Similarly, knock-down of Nck1 in primary CD4 T cells also caused decreased CD69 expression. However, no significant alterations of CD69 and IL-2 expression were found upon phytohaemagglutinin (PHA)/phorbol myristate acetate (PMA) stimulation. Knock-down of Nck1 had no effect on the proliferation of Jurkat T cells stimulated with either PHA or anti-T cell receptor (TCR) monoclonal antibody (C305). The reduced Nck1 expression in Jurkat cells was also associated with a reduced phosphorylation of extracellular regulated kinase (Erk)1 and Erk2 proteins upon CD3ε/CD28 stimulation. In conclusion, the decreased Nck1 protein in Jurkat T cells resulted in an impairment of TCR-CD3-mediated activation involving a defective Erk phosphorylation pathway.

Indexed as

Adaptive ImmunityAdaptor Proteins, Signal TransducingAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteApoptosisCD28 AntigensCD4-Positive T-LymphocytesCD69 AntigensElectroporationHumansInterleukin-1Jurkat CellsLectins, C-TypeLymphocyte ActivationMitogen-Activated Protein Kinase 1Adaptor Proteins, Signal TransducingAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteCD28 AntigensCD69 AntigensInterleukin-1Lectins, C-TypeMAPK1 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nck proteinOncogene ProteinsPhytohemagglutininsReceptor-CD3 Complex, Antigen, T-CellRNA, Small InterferingTetradecanoylphorbol Acetate

Identifiers

PMID22132889
PMCPMC3248091
OpenAlexW2158775554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.